Owkin licenses K Pro AI scientist and MOSAIC multimodal patient data to Servier for oncology research

The enrichment work sits with Owkin: it built K Pro as an AI scientist and assembled MOSAIC's multimodal patient data (7,000 tumour samples, six-plus modalities per sample) via federation across hospital partners, and licenses the two together to Servier. Servier operates the bundle inside its own oncology R&D, but the capability stack being leased was climbed by Owkin.

What Servier is paying for is a shortcut on specific oncology research decisions - which targets and biomarkers to prioritise in its 22 clinical-stage and 12 research oncology programmes - fed by a 7,000-sample spatial multi-omics atlas larger than any comparable dataset and an AI layer trained on it. The payer's call is which oncology programmes to progress, drop or combine.

What crosses to Servier under the licence is use of K Pro and the MOSAIC multimodal data for oncology research; what does not cross, on the public facts, is ownership of the MOSAIC substrate itself or of the K Pro model weights - Owkin retains the atlas and the AI scientist and continues to license them. Financial terms were not disclosed, so the exact scope of the field and term is not verifiable from the announcement.

Not determinable. Terms are undisclosed, and this matches the author's prior ruling on Owkin/Servier as a sell with a bundled reasoning layer protecting the rake; whether the licence fee is well-calibrated against the pipeline value Servier may extract cannot be read from the public release.